yooooooooooooooooooooooooo
1st Biotherapeutics, Inc.
240 Pangyoyeok-ro, Sampyeong-dong,
Bundang-gu, Seongnam-si, Gyeonggi-do,
South Korea
www.1stbio.com
info@1stbio.com
+82 31-8023-5332
Founded Year : 2016
Employee Number : 11-50
Ownership: Private
- 1st Biotherapeutics is a clinical stage biopharmaceutical company developing CNS penetrating kinase inhibitor, targeting neurodegenerative diseases, oncology and rare diseases.
- 1st Biotherapeutics recently launched TIO Biotherapeutics, Inc.; its wholly owned subsidary to discover and develop molecules in ImmunoOncology domain.
- In Jan 2019, 1st Biotherapeutics and twoXAR Inc., an artificial intelligence (AI)-driven biopharma company, signed collaboration to jointly discover and develop molecules targeting glioblastoma. Under the terms, twoXAR, to identify three drug candidates against glioblastoma, using its proprietary AI technology, while 1st Biotherapeutics will optimise candidates for further development. Financial details remains undisclosed.
- In Oct 2017, 1st Biotherapeutics and Neuraly Inc., collaborate to co-develop brain penetrating c-Abl inhibitors with improved safety profile for Parkinson’s disease. Under the terms, 1st Bio to perform the preclinical development, and Neuraly to test the drug candidates in various preclinical models of the disease. 1ST Biotherapeutics will retain all intellectual property generated in the collaboration. Financial terms remains undisclosed.
- In 2016, 1st Biotherapeutics raised 8 Mn won in Series A funding from undisclosed investors.
1st Biotherapeutics - Oncology Pipeline
| Molecule Name | Target | Phase | Indication | Molecule Type |
|---|---|---|---|---|
| 1ST-201 | Discovery | Solid Tumors | Small Molecule | |
| 1ST-205 | Undisclosed | Preclinical | Glioblastoma | Small Molecule |
- 1ST-201 targets a crucial pathway in immuno-oncology and aims to reverse the active immune suppression and stimulate functionality of effector immune cells and dendritic cells in tumor microenvironment.
- 1ST-205 is in development in collaboration with twoXar, against Glioblastoma, utilizing its AI driven drug discovery research platform.
